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ABSTRACT 
 
The treatment of multiple myeloma (MM), a largely incurable B-cell hematologic malignancy, is 
changing dramatically.  Autologous stem cell transplantation (SCT) and the approval of 2 new 
classes of drugs, immunomodulators and proteosome inhibitors, have resulted in improved 
response rates and increased overall survivals. Thalidomide, bortezomib, and lenalidomide 
have been combined with corticosteroids, alkylators, and anthracyclines in front-line MM 
treatment. Phase 2 and preliminary phase 3 studies have reported very high response rates and 
complete response (CR) rates formerly only seen with SCT. When patients with MM who have 
received these new drugs then proceed to transplant, major response rates are further 
increased. Due to limited follow-up, it is unclear whether these higher response rates translate 
into increased survival. 
 
Despite these improvements, the disease remains incurable for all but a small fraction of 
patients.  Allogeneic SCT is potentially curative, due in part to a graft-versus-myeloma effect but 
is limited by mortality.  Mortality can be reduced through the use of lower intensity conditioning 
regimens but this comes at a cost of higher rates of disease progression and relapse. Strategies 
to improve outcomes of allogeneic transplants include more intensive, yet non-myeloablative 
conditioning regimens, tandem transplants, peripheral blood cells, graft engineering, post 
transplant maintenance, and targeted conditioning therapies.  
 
Keywords: multiple myeloma, autologous stem cell transplantation, allogeneic stem cell 
transplantation. 
 
 Multiple myeloma (MM) is a clonal plasma cell tumor that responds to alkylating agents, 
corticosteroids, radiation therapy, and several new agents including thalidomide, lenalidomide, 
and bortezomib. New agents used in combinations with established drugs such as 
dexamethasone have shown impressive response rates, both in newly diagnosed and relapsed 
patients. 1-4 Despite the abundance of therapeutic agents, cure is almost never achieved with 
conventional chemotherapy.  Success in the management of refractory hematologic 
malignancies with stem cell transplantation (SCT) led to the exploration of this treatment for 
patients with MM. 5-8.  SCT from autologous or syngeneic donors allows the intensive use of 
chemotherapy +/- radiation to eradicate disease in the patient, since the most common dose-
limiting toxicity, marrow ablation, can be overcome by infusing stem and progenitor cells which 
accelerate marrow recovery. SCT from an allogeneic donor provides an additional immunologic 
graft-versus-myeloma effect resulting in more frequent and durable responses. 
 
Several prospective, randomized trials have been conducted comparing conventional 
chemotherapy to high dose therapy (HDT) using autologous SCT (ASCT) for patients with MM 9-
13 The French intergroup study demonstrated that high dose melphalan and total body 
irradiation (TBI) followed by ASCT, when applied as consolidation therapy after conventional 
chemotherapy induction, resulted in higher response rates, longer disease-free intervals, and 
better overall survival compared to continued conventional chemotherapy. 9,14 The Medical 
Research Council Myeloma VII trial compared combination chemotherapy to combination 
chemotherapy followed by single agent high dose melphalan and ASCT.  10 This large trial, with 
407 patients randomized, demonstrated a 12-month improvement in the median survival 
(p=0.04) and a similar improvement in event-free survival. Several other trials that allowed 
salvage ASCT in the conventional dose arm have shown higher response rates and longer 
progression-free intervals but survival benefits equivalent to up-front transplant. 15,16 Survival 
benefits are similar because most patients who undergo ASCT will relapse and salvage 
transplants benefit patients who progress after only conventional chemotherapy. 
 
As a result of these studies, ASCT has become a standard of care with more than 5900 ASCT 
performed in patients with MM in the United States reported to the Center for International Bone 
Marrow Transplant Registry in 2005; more than any other disease. Unfortunately, despite HDT 
and ASCT, the majority of patients with MM will relapse and die of recurrent disease. Relapses 
occur due to failure to eradicate disease in the patient or due to the reinfusion of malignant cells 
contained in the progenitor cell graft.  One randomized study, which evaluated the effect of 
removing myeloma cells from autologous stem cell grafts on outcome, found no improvement in 
responses, overall or progression-free survivals. 17 18 These results occurred even though the 
purging technique removed 3-4 logs of tumor cells from the grafts. One possible explanation 
that may account for this contradiction would be that despite the removal of 3-4 logs of tumor 
cells from the stem cell graft, there remained enough residual MM cells in the graft to lead to 
relapse. Alternatively, residual disease in the patient could be the major contributor to relapse.  
In that case, purging, even if 100% effective at removing malignant cells from the graft, will not 
have much impact on response rates or disease-free survival until improvements are made in 
the ability to eradicate residual host disease. Syngeneic donor transplant data could provide 
some insights into the relative contributions of infused tumor cells as a cause of relapse. A 
recent registry comparison of 43 syngeneic transplants compared with 170 autologous 
transplants suggested lower rates of relapse. This suggests that either infused tumor cells 
contribute to relapse or that a syngeneic graft versus myeloma effect can control residual 
disease. 19  
 
One way of dealing with minimal residual disease (MRD) in the patient after ASCT is to perform 
a second transplant utilizing HDT and ASCT or a reduced-intensity conditioning regimen 
followed by SCT from an allogeneic donor (see below). In randomized trials tandem ASCT can 
improve overall survival by about 10% compared to single ASCT. 20 21 This effect is small 
because patients who relapse after a single ASCT can receive a salvage ASCT, although there 
is controversy about the benefits of a salvage transplant. 22  Almost paradoxically, however, two 
studies have shown that the survival benefit of a second ASCT occurs mainly in patients who do 
not achieve a major response to their first transplant, while patients who are already in CR do 
not benefit from a second ASCT. It should be noted, however, that neither study was planned to 
perform such subgroup analyses and that both trial were conducted prior to the availability of 
new, more effective drugs now used for induction therapy.  This suggests that patients in CR 
after ASCT continue to harbor highly resistant residual MM cells. In addition, studies have 
determined that disease biology has a powerful impact on outcomes after ASCT. Several 
studies have shown that patients with cytogenetic abnormalities detected by fluorescence in-situ 
hybridization (FISH), specifically deletion 13, translocation 4:14 and deletion 17p, have 
significantly shorter progression-free and overall survivals than patients without them. 23 24 More 
recently it was shown that deletion 13 as a sole abnormality does not have the same prognostic 
significance in the absence of the 4:14 or 17p abnormalities. 25  Maintenance and consolidation 
therapy after ASCT has been explored as another way to improve responses, event-free and 
overall survivals. 26 At the present time there are conflicting data on the value of these 
strategies, although one study suggested thalidomide maintenance after ASCT is superior to a 
second ASCT. 27 28 29 
 
Another way to improve outcomes after transplant is to utilize more effective induction regimens 
with the goal of improving overall responses after ASCT. These novel drugs may also overcome 
some of the high-risk cytogenetic features in some patients. There are a large number of 
combinations incorporating novel drugs into induction regimens for patients with newly 
diagnosed MM. Relatively few trials, however, have reported comparisons of combinations 
incorporating thalidomide and bortezomib with more traditional drug combinations such as 
vincristine, adriamycin and dexamethasone (VAD) in patients proceeding to transplant (table 1). 
The French myeloma intergroup is comparing induction therapy with bortezomib and 
dexamethasone (BT) with VAD followed by ASCT. 30 This trial has completed accrual with 480 
patients and preliminary results indicate a substantially greater major response rate (≥VGPR) 
after BT compared to VAD. Following ASCT, the groups receiving BT or VAD induction had a 
further improvement in responses, but the advantage of BT remained. Survival, with a median of 
18 months of follow-up is not different between the BT and VAD groups.  The Italian consortium 
compared bortezomib, thalidomide and dexamethasone (BTD) to thalidomide and 
dexamethasone (TD). 31 The BTD regimen was substantially more effective that TD in producing 
major responses. Following transplant there was a further increase in major response rates for 
both regimens, but, again, the advantage for BTD remained. This would argue for a re-
examination of the relative merits of single v. tandem ASCT. 
 
The ECOG group compared lenalidomide plus either high-dose dexamethasone (480 mg/cycle) 
(RD) or low-dose dexamethasone (160 mg/cycle) (Rd). 32 After initial induction, 102 patients 
proceeded to ASCT at patient or physician preference while 91 remained on RD and 120 
remained on Rd. At 2 years, the projected overall survivals were 94% for ASCT, 80% for RD 
and 91% for Rd.  In a trial reported in 2006, among 204 patients who received induction with TD 
or VAD followed by ASCT, the major response rates after induction were 25% and 7% for TD or 
VAD, respectively. 33 Following transplant, however, the advantage for TD disappeared with 
major response rates of 44% and 41% for TD and VAD, respectively. It thus appears from 
preliminary data that some novel induction regimens result in a higher frequency of major 
responses than more traditional regimens and that ASCT further improves major response 
rates. It will require further follow-up to ascertain whether this translates into improved survival 
and it is important to emphasize that there are currently no data suggesting that long-term 
treatment with any novel drug combination is superior or even equivalent to ASCT.  
 
The observation that induction regimens employing new drugs produce complete responses 
(CR) in a substantial fraction of patients has opened the question of whether ASCT might be 
necessary for such patients. Small, retrospective studies with VAD based regimens have shown 
similar outcomes among patients who achieve CR prior to ASCT and those who achieve CR 
only after ASCT. 34  This does not necessarily mean that ASCT is of no value for such patients. 
In fact a more recent retrospective review showed that while patients achieving CR before and 
after ASCT has similar survivals, patients who came to transplant in nearCR but converted to 
CR after ASCT had better survival. 35 Thus, in order to more definitely determine the value to 
ASCT, patients who achieve CR with induction would need to be enrolled in a randomized study 
comparing ASCT with no transplant.  
 
Another strategy for improving response durability after ASCT is to employ vaccines in an effort 
to restore myeloma specific immunity in developing T and B cells. A variety of vaccines, 
dendritic cell infusions or activated T cell therapies are under study but as yet no solid data exist 
to suggest improvement in clinical outcomes. 36 37 38-40 
  
SCT from allogeneic donors is curative for 10-20% of patients with chemotherapy resistant, 
refractory hematologic malignancies and up to 80% of patients who are transplanted in 
remission. Much of the high response and curative potential of allografts is attributed to a “graft-
versus-tumor” effect. In patients with multiple myeloma, this effect has been well-documented 41 
42 43. In contrast, SCT from autologous or syngeneic donors provides little or no immunologic 
effect against the myeloma cell. Long-term follow-up of recipients of ASCT indicate a continuing 
risk of disease recurrence after 5 years and arguably few, if any, patients are cured. In contrast, 
allogeneic SCT with long-term follow-up appear to result in durable remissions and a lower risk 
of recurrence after 5 years.  44 Although treatment with high-dose chemoradiotherapy followed 
by allogeneic SCT is capable of producing remissions and long-term survival for patients with 
multiple myeloma, the transplant-related mortality of 25-50%, even in “good-risk” patients, limits 
the wider application of this approach. 
 
The high intensity conditioning regimens customarily used before allogeneic transplants are 
designed to produce cytoreduction and immunosuppression sufficient to allow establishment of 
the donor graft. The demonstrated efficacy of donor lymphocyte infusions in relapsed allograft 
patients suggests that the allogeneic graft-versus-myeloma effect is important for cure. This has 
led to the exploration of reduced intensity conditioning regimens, designed more for 
immunosuppression rather than cytoreduction, with the aim of establishing consistent donor 
engraftment with while minimizing toxicity and damage to normal host tissues. Furthermore, 
reduced intensity immunosuppression should decrease the period of severe pancytopenia that 
always occurs after high intensity conditioning. This technique, in theory, allows the graft-
versus-myeloma effect to operate while avoiding the high transplant-related mortality. 
 
One of the more widely used reduced intensity regimens was developed in Seattle based on 
canine transplant studies where it was shown that reliable allogeneic donor peripheral blood 
stem cell engraftment could be achieved with a very low dose of total body irradiation of 2 Gy 
and a combination of 2 potent immunosuppressive drugs including mycophenolic acid and 
cyclosporine. 45 This strategy was applied to 18 patients undergoing allogeneic transplant for 
multiple myeloma. Seven patients had refractory disease and 6 had failed a prior autograft. Two 
patients of the first 4 rejected the donor graft leading to the addition of fludarabine, which 
provided additional immunosuppression. 46 There were no further occurrences of rejection 
following the addition of fludarabine to the regimen.  Although only 1 of 18 patients died of 
transplant related toxicities, complete responses occurred in only 2 patients and only 3 others 
achieved partial responses. None of the responses were durable. These results confirmed that 
in multiple myeloma, the graft-versus-myeloma effect is relatively modest and that additional 
cytoreduction would be required to improve the responses using a reduced intensity allograft. 
Several studies of reduced intensity allografts from family members or unrelated donors have 
confirmed that results are poor when patients have failed a prior autologous transplant or have 
chemotherapy-resistant disease. 47 48 49 Two German studies and a study from MD Anderson 
confirmed 2 year survivals of 26-50% for patients who had failed 1 or more autologous 
transplants.  A study combining data from several centers including approximately 120 patients 
found that relapse from a prior autologous transplant was the most significant risk factor for 
transplant mortality (HR 2.80; p=0.02), relapse (HR 4.14; p<0.001), and death (HR 2.69; 
p=0.005). 50  A large EBMT registry trial found equivalent overall survival and inferior 
progression-free survival when reduced intensity allografts were compared with ablative 
allografts. 51 At least one trial comparing autologous to reduced intensity allografts following 
relapse from a prior autologous transplant found no differences in progression-free and overall 
survival. 52 A more recent study has demonstrated that a second ASCT performed only after 
relapse or progression can result in major responses with prolonged survival 53 Thus it remains 
to be determined whether or not an reduced intensity allograft or a second autograft is the best 
choice once patients have failed a prior autograft. 
 
In an effort to improve cytoreduction, patients with MM who had not received a prior high dose 
regimen first received HDT and ASCT followed by a reduced intensity allograft. Patients had 
autologous peripheral blood stem cells collected, followed by melphalan 200 mg/m2 and 
reinfusion of autologous stem cells to provide cytoreduction and some immunosuppression. In 
this way the high dose therapy is separated in time from the introduction of the allograft. Two to 
4 months later, after recovery from the first autologous stem cell transplant, patients received a 
regimen of 200 cGy total body irradiation, mycophenolic acid and cyclosporine with allogeneic 
peripheral blood stem cells.  Fifty-four patients ages 29-71 years, median age 52 years, 
received this tandem autologous, allogeneic transplant strategy. 54 All patients were stage II or 
III and 48% had refractory or relapsed disease. One patient died of cytomegalovirus pneumonia 
after the initial autologous stem cell transplant, 1 patient progressed after the autograft, and 52 
proceeded to allogeneic stem cell transplant. All 52, except 1, achieved full donor chimerism 
with a single patient requiring donor lymphocyte infusions on day 84 for partial chimerism. The 
overall transplant mortality was 22% and the complete remission rate was 57%. Four patients 
developed severe acute GVHD (grades 3-4) and chronic GVHD developed in 60%.  With a 
median follow-up of 60 months after allograft, the survival at 60 months was 69%, and the 
progression-free survival 40%. In a more recent update of this strategy, 102 patients have 
received this treatment with a median follow-up of 6.3 years. The estimated 5-year overall 
survival, progression free survivals and transplant-related mortality were 64%, 36% and 18% 
respectively. 55   
 
Planned tandem autologous, followed by reduced intensity allografting have been reported in 
studies containing approximately 120 patients (table2). Autologous transplant was performed 
approximately 2-6 months prior to planned allografting. The allograft regimens utilized 
melphalan 100-140 mg/m2 plus fludarabine or 2Gy TBI or cyclophosphamide plus fludarabine. 
These studies reported transplant-related mortalities of 18-24%, chronic GVHD of 7-60%, and 
survivals of 58-74% at 2 years, 86% at 3 years and 69% at 5 years. Complete response rates 
ranged from 28-73%.  Chronic GVHD has been associated with a lower rate of disease 
recurrence, although this is controversial since only occasional studies have shown benefit. 56   
 
No prospective randomized trials have been published comparing ablative with non-ablative 
conditioning regimens for the transplant of patients with multiple myeloma. There are, however, 
a number of studies reported or underway comparing tandem autologous transplants to a 
tandem autologous-non-ablative allograft approach. The randomization for these studies was 
“genetic,” in that patients with available related donors were typed and if an HLA identical donor 
was identified, they were offered a non-ablative transplant as the second transplant. While not 
truly randomized, they provide some comparative data on the relative risks and benefits of the 2 
techniques. 
 
A French trial using 2 parallel studies compared outcomes in 284 patients with multiple 
myeloma who were high risk by virtue of elevated beta-2-micoglobulin and deletion of 
chromosome 13 by FISH. 57 All patients first had an autologous transplant with high dose 
melphalan. The 65 patients with HLA matched donors underwent an allogeneic transplant on 
one protocol after conditioning with busulfan, fludarabine and a high dose of anti-thymocyte 
globulin 12.5 mg/kg. They were compared to 219 patients without donors who were treated on 
another protocol with a second autologous transplant with melphalan 220 mg/m2.  Transplant 
mortality was 5% for the tandem auto group compared to 11% for the auto-allo group. The 
complete response and very good PR rates were 51% and 62% respectively for the tandem 
auto and auto-allo groups. With a relatively short follow-up of a median 2 years, the overall 
survivals and event free survivals were not statistically different, 35% v. 41%, and 25% v. 30% 
for the tandem auto and auto-allo studies, respectively. Although these results indicate that 
patients with high-risk features do not benefit from a tandem auto-reduced intensity allograft 
approach, the regimen utilized a high dose of ATG 12.5 mg/kg. This resulted in a low incidence 
of acute and chronic GVHD (7%) but a relatively low complete response rate (33% of evaluable 
patients).  This study agrees with another report analyzing the outcome of RIC allografting in 
patients with or without del13. 58 This study demonstrated that del13 was an independent, 
adverse risk factor for overall survivals and progression free survivals after reduced intensity 
allografting due primarily to a greater risk of relapse. Whether or not any allograft procedure can 
overcome this adverse risk factor remains to be determined, but a retrospective study of 101 
patients who received reduced intensity allografts showed similar survivals between patients 
with normal cytogenetics or the 4:14 translocations, but worse outcomes in patients with 17p 
deletions. 59 
 
A more recent study prospectively assigned 162 patients with stage II or II multiple myeloma to 
induction with VAD for 2-3 cycles, followed by autologous peripheral blood stem cell collection 
following cyclophosphamide and granulocyte colony stimulating factor. 60 All patients then 
received high dose melphalan followed by autologous peripheral blood stem cells. Patients with 
an HLA-identical sibling (N=80) were assigned to receive a reduced intensity allogeneic 
transplant using the Seattle regimen, while patients without a matched sibling (N=82) were 
assigned to receive a second course of high dose melphalan and ASCT. Only 58 and 46 
patients in the auto-allo and auto-auto groups completed their assigned treatments.  The 
complete response rate was 26% with the tandem auto and 55% with the auto-allo group 
(p=0.004). The transplant mortality was 2% and 10% for the tandem auto and auto-allo groups, 
respectively, p=ns. Based on intention to treat, and with a 45-month median follow-up, the 
median overall survivals were 54 months and 80 months, for the tandem auto v. auto-allo 
groups, respectively, p=0.01. The progression-free survivals were 29 months v. 35 months for 
the auto-auto and auto-allo groups respectively, p=0.02.  An important strength of this trial is the 
treatment assignment based solely on donor availability and analysis on intention to treat. 
These results suggest a possible advantage for the auto-allo approach, although longer follow-
up is needed. One concern in this study was that high lactate dehydrogenase and low platelet 
count at diagnosis were both independent predictors of survival and progression-free survival. 
This would suggest that allogeneic transplant may not be able to overcome some high-risk 
prognostic factors.  
 
In another strategy, a Spanish cooperative group reported on 114 patients who received ASCT 
after a melphalan or busulfan-melphalan regimen and achieved less than a near CR. 56  Eighty-
eight patients with no donors received a second ASCT after a regimen of cyclophosphamide, 
carmustine and etoposide, while 26 patients with donors received a reduced intensity allograft 
after a fludarabine, melphalan regimen. The TRM, and CR rates for the ASCT and allo SCT 
groups were 5% and 16% and 11% and 33%, respectively. With a relatively short follow-up of 
19-26 months, there were no survival differences, but a trend in EFS favoring the allografts.  
  
It is clear that reduced intensity allogeneic transplant regimens can result in reliable donor 
engraftment with a relatively low mortality compared to high dose regimens. The immunologic 
effect of the allograft is, however, relatively modest resulting in a reduced rate of CR and a 
higher rate of progression compared to ablative regimens. Thus, it appears that substantial 
cytoreduction pre-allografting is required in order to facilitate the success of a reduced intensity 
allograft.  Preliminary results suggest the tandem auto/reduced intensity allogeneic strategy can 
result in CR in over 50% of patients with multiple myeloma; similar to what can be achieved with 
a high dose conditioning regimen. Reduced intensity regimens are a promising strategy to 
ensure reliable engraftment, low mortality and high response rates, as well as the ability to 
expand this technique to older patients or patients with co-morbid conditions.  It will be 
important, however, to have longer follow-up of patients transplanted with non-ablative regimens 
in order to document the durability of these remissions since most studies to date do not 
demonstrate a plateau in disease free survival.  
 
In summary there has been important progress in the treatment of MM including new drugs and 
combinations, ASCT, and reduced intensity allografts.  Most studies point to the achievement of 
at least a VGPR or better as a surrogate for survival. Despite these advances MM remains an 
incurable disease for the majority of patients. The challenge at present is how to integrate the 
best combinations of new and old drugs used for initial induction, followed by ASCT and 
possibly an RIC allograft in order to achieve long term disease control. The availability of 
novel drug combination for induction will likely improve the overall survival of patients 
proceeding to ASCT. It will likely require completely novel strategies such as 
radioisotope targeting as part of the conditioning regimen to cure patients proceeding to 
ASCT.  
 
Table 1  Ongoing Trials of Novel Drug Combinations in Patients Proceeding to Autologous Stem Cell 
Transplantation 
 
Reference No 
Patients 
Induction Regimens              Major Response After  
     Induction%             Autograft % 
 ≥nCR     ≥VGPR     ≥nCR    ≥VGPR 
Survival at 
(yr) 
Harousseau 
30 
240 
242 
Bortezomib, dex1 
Vincristine, dex, adriamycin 
21 
8 
47 
19 
35 
24 
62 
42 
92% (1.5) 
89% (1.5) 
Cavo 
31 
74 
79 
Bortezomib, thalidomide, dex 
Thalidomide, dex 
36 
9 
60 
27 
57 
28 
77 
54 
nr2 
Rajkumar 
32 
102 
91 
120 
Lenalidomide, low or high dex->ASCT 
Lenalidomide, high dex 
Lenalidomide, low dex 
 
43 
23 
 
52 
44 
 
nr 
 
nr 
  94% (2)4 
80% (2) 
91% (2) 
Macro 
33 
100 
104 
Thalidomide, dex 
Vincristine, dex, adriamycin 
nr 25 
7 
nr 44% 
41% 
nr 
 
 
 
 
 
1dex=dexamethasone 
2nr=not reported 
3bone marrows were not required on study for confirmation of CR 
4Only these patients received stem cell transplant (not randomized); others remained on induction regimen. High 
dex=480 mg/cycle, low dex=160 mg/cycle 
 
Table 2. Phase 2 Trials of Tandem Autologous-Reduced Intensity Allogeneic Transplantation from Related and 
Unrelated Donors for the treatment of Multiple Myeloma 
 
Reference No Regimen # 
Tandem
Auto 
Proph 
GVHD 
AGVHD
%, 2-4 
CGVH 
% 
 
TRM 
% 
CR 
% 
%Survival 
 at (yr) 
Maloney 
54 
54 
(0) 
TBI 2Gy, Flu 54 CSA   
Mmf 
45 60 22 57 69 (5) 
Lee 
61 
451 
(12) 
HDM 100 
(TBI2Gy,Flu) 
12 CSA 58 13 38 
10 t 
64 36 (3) 
86 t 
Kroger 
62 
17 
(8) 
HDM100, 
Flu, ATG 
17 CSA,  
Mtx     
38 7 18 73 74 (2) 
Kroger 
63 
21 
(21) 
HDM100-
140, Flu, 
ATG 
9 CSA,  
Mtx     
38 12 24 40 74 (2) 
Galimberti 
64 
20 
(0) 
TBI 2Gy,Flu 
(10) 
Cy, Flu (10) 
20 CSA 
Mmf 
25 30 20 35 58 (2) 
Perez-Simon  
65 
29 
(nr) 
Mel,Flu 10 CSA 
Mtx 
41 51 21 28 60 (2) 
Vesole 
66 
23 
(0) 
Flu 
Cyclophos 
23 CSA 
steroid
172 39 9 33 78 (2) 
 
Notes:  No.=total number of patients (number from matched unrelated donors); Regimen  HDM=high dose 
melphalan, TBI=total body irradiation, Flu=fludarabine, Cy=cyclophosphamide, ATG= anti-thymocyte globulin; # 
Tandem Auto-planned prior autologous transplant; ProphGVHD graft-versus-host disease prophylaxis, 
CSA=cyclosporine, , Mtx=methotrexate, Mmf=mycophenolic acid, AGVHD=acute graft-versus-host-disease; 
CGVH=chronic GVHD; TRM=transplant related mortality rate; CR=complete response rate 
114 patients given DLI, t TRM or survival for tandem patients 
2 Only grade 3-4 GVHD reported
 
 
Table 3  Comparison Trials of Tandem Autologous Transplant with Tandem Autologous - Reduced Intensity Allografting 
 
 
Author Regimens Number
 
TRM Response 
CR/VGPR 
DFS (f/u yr) OS (f/u yr) 
Auto mel 200/220 219 5% 33%/18% 0% 5yr 44% 5yr Garban1 
  57 
Auto mel200 
Allo bu,flu,ATG 
652 11% 33%/29% 0% 5yr 33% 5yr 
Auto mel 200 803 4% 26%/nr7 20% 4yr 53% 4 yr Bruno 60 
Auto mel200 
Allo 2Gy TBI 
824 10% 55%/nr 42% 4yr5 75% 4 yr5 
Auto BuMel-Mel, 
Auto CBV 
85 5% 11%/6% Med 31mo Med 58 mo Rosinol6 
56 
Auto BuMel-Mel 
Allo FluMel140 
25 16% 40%/nr “not reached”  “not reached” 
 
1 high risk patients with elevated B-2M or deletion 13 by FISH. 
219/65 patients did not receive the reduced intensity allograft 
3 46/80 patients completed the tandem autograft 
4 58/82 patients received the reduced intensity allograft 
5 statistically significant 
6 only patients not in ≥ nCR after autograft 
7nr = not reported 
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